Therapies that deliver hydrogen sulfide to cells could one day become the basis of new treatments for obesity and related ...

Some Rice University researchers have partnered with other institutions to continue bioelectrical implant treatment ...

Authorizing Medicare to cover weight loss drugs would increase federal spending by about $35 billion from 2026 to 2034 ...

France is the latest European country to refuse to cover weight loss drugs through its national insurance programme.

WeightWatchers said on Tuesday it would offer a compounded version of Novo Nordisk's popular obesity drug Wegovy as part of ...

Just 800 of the 13,500 patients eligible to start receiving Wegovy, which can help obese people lose 15% of their body weight ...

A CNBC investigation into illegal weight loss drugs reveals a marketplace where criminals brazenly counterfeit the drugs or ...

With the resolution, compounding pharmacies are no longer able to produce tirzepatide. And the FDA highlighted the point to ...

A review of the recent evidence suggests that GLP-1 drugs, such as semaglutide, could protect brain health and cognitive ...

There’s a war brewing over blockbuster weight loss medications — and patients are now getting caught in the crossfire.

Only a fifth of large U.S. companies cover pricey GLP-1 weight-loss drugs like Wegovy and Zepbound in their health insurance ...

New drugs from public and private companies are expected to saturate the obesity drug market. Novo Nordisk and Eli Lilly are currently dominating the weight loss drug market, but biopharmaceutical ...